Nutriband Inc. (NTRB): Price and Financial Metrics
GET POWR RATINGS... FREE!
NTRB Stock Price Chart Interactive Chart >
NTRB Price/Volume Stats
| Current price | $4.83 | 52-week high | $15.00 |
| Prev. close | $5.01 | 52-week low | $2.81 |
| Day low | $4.67 | Volume | 14,467 |
| Day high | $4.94 | Avg. volume | 296,645 |
| 50-day MA | $4.44 | Dividend yield | N/A |
| 200-day MA | $4.85 | Market Cap | 37.78M |
Nutriband Inc. (NTRB) Company Bio
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida
Latest NTRB News From Around the Web
Below are the latest news stories about NutriBand Inc that investors may wish to consider to help them evaluate NTRB as an investment opportunity.
NTRB: Hitting Milestones on Path toward Regulatory Approval & CommercializationBy M. Marin NTRB:NASDAQ READ THE FULL NTRB RESEARCH REPORT Laying the groundwork to move forward Nutriband Inc. (NTRB:NASDAQ), an emerging a biopharma and medical device company that is developing a portfolio of transdermal pharmaceutical products, has hit several milestones to move AVERSA Fentanyl, a Fentanyl transdermal patch that leverages its AVERSA™ technology, towards regulatory approval |
Nutriband Inc.'s Patent, 'Abuse and Misuse Deterrent Transdermal System’ Published by the United States Patent and Trademark Office Following Recent Issuance NoticeORLANDO, FL / ACCESSWIRE / February 16, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that the United States Patent and Trademark Office (USPTO) has published its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™. |
Nutriband Inc. To Participate in The Benzinga All Access Event on February 4ORLANDO, FL / ACCESSWIRE / February 4, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) will be participating in the Benzinga ALL ACCESS, which will take place on February 4. |
Nutriband Issued Full US Patent for Its Aversa(TM) Abuse Deterrent Transdermal Platform by United States Patent and Trademark OfficeORLANDO, FL / ACCESSWIRE / January 28, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced the receipt of an Issue Notification from the United States Patent and Trademark Office (USPTO) for its United States patent entitled, "Abuse and Misuse Deterrent Transdermal System," that protects its AVERSA™ transdermal abuse deterrent technology. |
Nutriband Inc. Expands Product Development Pipeline for Its AVERSA(TM) Platform Abuse Deterrent TechnologyORLANDO, FL / ACCESSWIRE / January 18, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced an expanded product development pipeline for its proprietary AVERSA™ abuse deterrent transdermal technology. |
NTRB Price Returns
| 1-mo | 11.55% |
| 3-mo | 20.75% |
| 6-mo | -20.17% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -52.08% |
| 2021 | -32.80% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...